VALN
Price:
$6.02
Market Cap:
$437.28M
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine can...[Read more]
Industry
Biotechnology
IPO Date
2021-05-05
Stock Exchange
NASDAQ
Ticker
VALN
According to Valneva SE’s latest financial reports and current stock price. The company's current ROE is -20.21%. This represents a change of 163.67% compared to the average of -7.67% of the last 4 quarters.
The mean historical ROE of Valneva SE over the last ten years is -36.64%. The current -20.21% ROE has changed -44.84% with respect to the historical average. Over the past ten years (40 quarters), VALN's ROE was at its highest in in the December 2021 quarter at 101.13%. The ROE was at its lowest in in the June 2022 quarter at -155.97%.
Average
-36.64%
Median
-32.08%
Minimum
-83.17%
Maximum
2.28%
Discovering the peaks and valleys of Valneva SE ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 6.35%
Maximum Annual ROE = 2.28%
Minimum Annual Increase = -156.61%
Minimum Annual ROE = -83.17%
Year | ROE | Change |
---|---|---|
2023 | -79.09% | 21.33% |
2022 | -65.19% | 51.44% |
2021 | -43.04% | -48.25% |
2020 | -83.17% | 6.35% |
2019 | -1.29% | -156.61% |
2018 | 2.28% | -118.40% |
2017 | -12.39% | -74.80% |
2016 | -49.16% | 244.15% |
2015 | -14.28% | -32.34% |
2014 | -21.11% | 26.91% |
The current ROE of Valneva SE (VALN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-62.44%
5-year avg
-54.36%
10-year avg
-36.64%
Valneva SE’s ROE is less than Advaxis, Inc. (962.69%), greater than NuCana plc (-222.84%), greater than Sage Therapeutics, Inc. (-60.43%), greater than SELLAS Life Sciences Group, Inc. (-17349.62%), greater than Third Harmonic Bio, Inc. (-6.80%), greater than Cullinan Oncology, Inc. (-28.37%), greater than Edgewise Therapeutics, Inc. (-28.01%), greater than Rallybio Corporation (-74.08%), greater than Monte Rosa Therapeutics, Inc. (-70.40%), greater than Tyra Biosciences, Inc. (-27.13%), greater than C4 Therapeutics, Inc. (-44.60%), greater than Stoke Therapeutics, Inc. (-57.89%), greater than Revolution Medicines, Inc. (-34.57%), less than Opthea Limited (360.05%), less than Inhibrx, Inc. (1.62%), greater than Mineralys Therapeutics, Inc. (-42.61%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Anebulo Pharmaceuticals, Inc. (-122.97%), greater than Nuvation Bio Inc. (-98.79%), greater than Instil Bio, Inc. (-55.57%), greater than Connect Biopharma Holdings Limited (-20.84%), greater than Neoleukin Therapeutics, Inc. (-47.64%), greater than Graphite Bio, Inc. (-57.96%),
Company | ROE | Market cap |
---|---|---|
962.69% | $852.67K | |
-222.84% | $7.88M | |
-60.43% | $482.30M | |
-17349.62% | $78.49M | |
-6.80% | $605.37M | |
-28.37% | $1.04B | |
-28.01% | $2.77B | |
-74.08% | $45.64M | |
-70.40% | $383.58M | |
-27.13% | $1.27B | |
-44.60% | $455.55M | |
-57.89% | $797.09M | |
-34.57% | $7.71B | |
360.05% | $594.00M | |
1.62% | $253.18M | |
-42.61% | $601.69M | |
-47.03% | $555.26M | |
-122.97% | $53.94M | |
-98.79% | $732.32M | |
-55.57% | $382.10M | |
-20.84% | $68.48M | |
-47.64% | $8.20M | |
-57.96% | $185.19M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Valneva SE using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Valneva SE or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Valneva SE's ROE?
How is the ROE calculated for Valneva SE (VALN)?
What is the highest ROE for Valneva SE (VALN)?
What is the 3-year average ROE for Valneva SE (VALN)?
What is the 5-year average ROE for Valneva SE (VALN)?
How does the current ROE for Valneva SE (VALN) compare to its historical average?